A fluorescence displacement assay for antidepressant drug discovery based on ligand-conjugated quantum dots.

Chang JC, Tomlinson ID, Warnement MR, Iwamoto H, DeFelice LJ, Blakely RD, Rosenthal SJ
J Am Chem Soc. 2011 133 (44): 17528-31

PMID: 21970724 · PMCID: PMC3235909 · DOI:10.1021/ja204301g

The serotonin (5-hydroxytryptamine, 5-HT) transporter (SERT) protein plays a central role in terminating 5-HT neurotransmission and is the most important therapeutic target for the treatment of major depression and anxiety disorders. We report an innovative, versatile, and target-selective quantum dot (QD) labeling approach for SERT in single Xenopus oocytes that can be adopted as a drug-screening platform. Our labeling approach employs a custom-made, QD-tagged indoleamine derivative ligand, IDT318, that is structurally similar to 5-HT and accesses the primary binding site with enhanced human SERT selectivity. Incubating QD-labeled oocytes with paroxetine (Paxil), a high-affinity SERT-specific inhibitor, showed a concentration- and time-dependent decrease in QD fluorescence, demonstrating the utility of our approach for the identification of SERT modulators. Furthermore, with the development of ligands aimed at other pharmacologically relevant targets, our approach may potentially form the basis for a multitarget drug discovery platform.

MeSH Terms (17)

Amines Animals Antidepressive Agents Binding Sites Dose-Response Relationship, Drug Drug Discovery Fluorescence Humans Ligands Oocytes Paroxetine Quantum Dots Serotonin Plasma Membrane Transport Proteins Spectrometry, Fluorescence Structure-Activity Relationship Time Factors Xenopus

Connections (3)

This publication is referenced by other Labnodes entities: